Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the shares following the Q4 report. The firm says the Vyjuvek launch continues to mature while the company’s pipeline serves as an “upside lever.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Strong Growth Prospects and Pipeline Catalysts Justify Buy Rating
- Krystal Biotech Reports Robust 2024 Financial Growth
- Buy Recommendation for Krystal Biotech Based on Strong Performance and Strategic Pricing
- Krystal Biotech price target raised to $218 from $212 at Chardan
- Krystal Biotech: Strong Financials and Strategic Growth Support Buy Rating